US Patent Issued to Amgen on May 12 for "Combination of LILRB1/2 pathway inhibitors and PD-1 pathway inhibitors" (Canadian, American Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,106, issued on May 12, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Combination of LILRB1/2 pathway inhibitors and PD-1 pathway inhibitors" was invented by Xin Yu (Foster City, Calif.), Wenjun Ouyang (Foster City, Calif.), Chi-Ming Kevin Li (Thousand Oaks, Calif.), Jackson Graeme Egen (San Mateo, Calif.), Oh Kyu Yoon (Pacifica, Calif.), Ian Halsey Driver (San Francisco), Shunsuke Takenaka (Burnaby, Canada), Christy Ann Thomson (Port Moody, Canada) and Hongyu Wang (Coquitlam, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, a...